Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation

Forest Laboratories, Inc. (NYSE: FRX - News) today announced preliminary results of a Phase III study of memantine HCl (currently marketed as Namenda®, a twice-daily immediate- release formulation) in a novel once-daily formulation. The study evaluated the efficacy, safety, and tolerability of an innovative, proprietary, 28 mg memantine extended-release, once-daily formulation compared to placebo in outpatients with moderate to severe Alzheimer's disease currently treated with a cholinesterase inhibitor. The results indicate that patients treated with memantine 28 mg extended-release formulation experienced statistically significant benefits in cognition and clinical global status compared to placebo. Additional data from the study are expected to be presented later in the year.